Top

Published in:

01-11-2006 | Poster Presentation

Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial

Authors: M Harvie, M Chapman, J Cuzick, A Flyvbjerg, P Hopwood, S Jebb, G Parfitt, A Howell

Published in: Breast Cancer Research | Special Issue 2/2006

Excerpt

Postmenopausal breast cancer risk increases twofold in women who gain significant amounts of weight [1] and there is evidence that energy restriction may reduce risk [2]. Animal studies indicate that intermittent energy restriction (IER) reduces risk and may be superior to continuous energy restriction (CER) [3]. We have shown chronic energy restriction reduces biomarkers of breast cancer in women at risk but is hard to maintain. We hypothesise that IER may be superior to CER in reducing biomarkers of breast cancer risk and may also be more acceptable to women. …

Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekens CH, Rosner B, Speizer FE, Willett WC: Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997, 278: 1407-1411. 10.1001/jama.278.17.1407.CrossRefPubMed

Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA: Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2005, 14: 656-661. 10.1158/1055-9965.EPI-04-0001.CrossRefPubMed

Cleary MP, Jacobson MK, Phillips FC, Getzin SC, Grande JP, Maihle NJ: Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor-alpha female mice. Cancer Epidemiol Biomarkers Prev. 2002, 11: 836-843.PubMed

Title: Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial
Authors: M Harvie
M Chapman
J Cuzick
A Flyvbjerg
P Hopwood
S Jebb
G Parfitt
A Howell
Publication date: 01-11-2006
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue Special Issue 2/2006
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1584

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 2/2006

Role of BRCT motif containing proteins in Chk1 activation

Role of the Brk tyrosine kinase in breast cancer progression

Expression of adrenomedullin in long-term oestrogen-deprived human breast cancer cells

Breast cancer in relation to childhood parental divorce and early adult psychiatric disorder in a British birth cohort

Evaluation of migration-stimulating factor expression for breast cancer diagnosis and prognosis

Functional analysis of the breast cancer associated transcriptional repressor PLU-1/JARID1B

Keynote webinar | Spotlight on antibody–drug conjugates in cancer